Wolfe Research initiated coverage of Praxis Precision (PRAX) with an Outperform rating and $500 price target The firm launched coverage of the neuroscience biotech sector with a “portfolio of high conviction names across multiple therapeutic areas.” Wolfe believes Praxis could become a key player in neurology for both essential tremor and epilepsy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines Maps Aggressive Path to Market
- Praxis Precision price target raised to $700 from $500 at Truist
- Praxis Precision price target raised to $130 from $95 at Wedbush
- Praxis Precision price target raised to $412 from $357 at Deutsche Bank
- Praxis Precision price target raised to $433 from $275 at Baird